SiteOne Therapeutics, headquartered in Bozeman, Montana, was founded with technology invented at Stanford University that represents a potential revolutionary advancement in the treatment of acute and chronic pain. The company's therapeutic candidates are highly selective sodium ion channel 1.7 (NaV1.7) inhibitors based on naturally occurring small molecules. Given the critical role NaV1.7 plays in the generation and conduction of pain signals, combined with the urgent need for new, non-opioid pain therapies, SiteOne is focused on advancing its lead product for the treatment of moderate to severe pain. Additional opportunities with the company's technology include long-acting analgesics, PET imaging diagnostics for pain and other pain indications. SiteOne owns worldwide development and commercialization rights to its development programs through an exclusive license from Stanford University.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/15/15 | undisclosed |
Biobrit Mission Bay Capital Next Frontier Capital Sears Capital Management Z Investments | undisclosed | |
| 01/09/17 | $15,000,000 | Series B |
Amgen Business Development Biobrit Mission Bay Capital Next Frontier Capital Sears Capital Management Z Investments | undisclosed |
| 12/18/24 | $100,000,000 | Series C |
BSQUARED Capital Mission BioCapital Novo Holdings  OrbiMed Advisors Wellington Management | undisclosed |
